Rhesus disease, also known as hemolytic disease of the fetus and newborn (HDFN), is a condition in which a pregnant woman's antibodies destroy her baby's blood cells.
While it doesn't harm the mother, it can lead to anemia and jaundice in the newborn, and in severe cases, kernicterus, causing permanent brain damage or hydrops fetalis, resulting in heart failure or fluid buildup.
With a mortality rate of up to 24% in newborns, Rh-negative pregnant women with Rh-positive partners are at risk.

Routine screening of pregnant women can prevent Rhesus disease.

If a mother is at risk, healthcare providers can administer anti-D (Rh) immunoglobulin, typically twice during pregnancy at 28 weeks and shortly after birth.
This medication prevents the mother's immune system from attacking the child's blood cells and is well-tolerated.

The EldonCard is a reliable tool for point-of-care blood typing of ABO and Rhesus systems, offering immediate results within two minutes.

The durable nature of the EldonCard makes it the preferred method in development and humanitarian contexts,
including areas with complex supply chains or affected by disasters or armed conflicts.
This allows for swift blood typing, potentially saving lives.

The EldonCard's durability and simplicity make it the method of choice for Rhesus screening,
enabling millions of women to receive appropriate immunoprophylaxis, potentially saving over 150,000 lives annually.

Eldon has specifically developed a Rhesus card for use in birth centers, clinics, and abortion clinics.